NEFL and spinal muscular atrophy, type III: Overall, our studies suggest that both pNfH and NfL are reduced by Nusinersen administration in a significant proportion of SMA type 3 patients as early as six months after the first treatment, and mandate further investigation on the accuracy of neurofilaments as markers of treatment response.